Impact of paraoxonase polymorphism (Q192R) on endothelial function in intact coronary circulation

Hypertension Research

Volumn 29, Issue 6, 2006, Pages 417-422

  Yamane, Tetsunobu ^a   Matsumoto, Tetsuya ^a   Nakae, Ichiro ^a   Takashima, Hiroyuki ^a   Tarutani, Yasuhiro ^b   Tamaki, Shinji ^b   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Kohka Public Hospital   (Japan)

Author keywords

Bradykinin; Coronary circulation; Endothelium; Paraoxonase 1 (PON1)

Indexed keywords

ACETYLCHOLINE; ARYLDIALKYLPHOSPHATASE 1; BRADYKININ;

ADULT; AGED; ANALYSIS OF VARIANCE; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY SPASM; DOPPLER FLOWMETRY; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; GUIDE WIRE; HEART CATHETERIZATION; HUMAN; MALE; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROVOCATION TEST; QUANTITATIVE ANALYSIS; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION; VASOMOTOR REFLEX;

ACETYLCHOLINE; ADULT; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; ARYLDIALKYLPHOSPHATASE; BRADYKININ; CORONARY CIRCULATION; CORONARY VASOSPASM; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENDOTHELIUM-DEPENDENT RELAXING FACTORS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; VASOCONSTRICTION; VASOMOTOR SYSTEM;

EID: 33746277550     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.417     Document Type: Article

References (28)

1. Raitakari OT, Pitkanen OP, Lehtimaki T, et al: In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J Am Coll Cardiol 1997; 30: 97-102.
2. Mackness MI, Abbott C, Arrol S, Durrington PN: The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993; 294: 829-834.
3. Ruiz J, Blanche H, James RW, et al: Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346: 869-872.
4. Serrato M, Marian AJ: A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96: 3005-3008.
5. Odawara M, Tachi Y, Yamashita K: Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 2257-2260.
6. Quyyumi AA: Prognostic value of endothelial function. Am J Cardiol 2003; 91: 19H-24H.
7. Ito T, Yasue H, Yoshimura M, et al: Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. Hum Genet 2002; 110: 89-94.
8. Bauters C, Amant C, Boullier A, et al: Paraoxonase polymorphism (Gln192Arg) as a determinant of the response of human coronary arteries to serotonin. Circulation 2000; 101: 740-743.
9. Malin R, Knuuti J, Janatuinen T, et al: Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med 2001; 79: 449-458.
10. Nakashima M, Mombouli JV, Taylor AA, Vanhoutte PM: Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest 1993; 92: 2867-2871.
11. Toda N, Okamura T: Endothelium-dependent and -independent responses to vasoactive substances of isolated human coronary arteries. Am J Physiol 1989; 257: H988-H995.
12. Yasue H, Horio Y, Nakamura N, et al: Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 1986; 74: 955-963.
13. Ohira N, Matsumoto T, Tamaki S, et al: Angiotensin-converting enzyme insertion/deletion polymorphism modulates coronary release of tissue plasminogen activator in response to bradykinin. Hypertens Res 2004; 27: 39-45.
14. Tarutani Y, Matsumoto T, Takashima H, Yamane T, Horie M: Brachial artery flow-mediated vasodilation is correlated with coronary vasomotor and fibrinolytic responses induced by bradykinin. Hypertens Res 2005; 28: 59-66.
15. Tamaki S, Iwai N, Tsujita Y, Nakamura Y, Kinoshita M: Polymorphism of alpha-adducin in Japanese patients with essential hypertension. Hypertens Res 1998; 21: 29-32.
16. Tamaki S, Nakamura Y, Tsujita Y, et al: Polymorphism of the angiotensin converting enzyme gene and blood pressure in a Japanese general population (the Shigaraki Study). Hypertens Res 2002; 25: 843-848.
17. Tamaki S, Nakamura Y, Tabara Y, et al: Combined analysis of polymorphisms in angiotensinogen and adducin genes and their effects on hypertension in a Japanese sample: the Shigaraki Study. Hypertens Res 2005; 28: 645-650.
18. Matsumoto T, Takashima H, Ohira N, et al: Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin. J Am Coll Cardiol 2004; 44: 451-457.
19. Tomiyama H, Kushiro T, Okazaki R, Yoshida H, Doba N, Yamashina A: Influences of increased oxidative stress on endothelial function, platelets function, and fibrinolysis in hypertension associated with glucose intolerance. Hypertens Res 2003; 26: 295-300.
20. Hirooka Y, Eshima K, Setoguchi S, Kishi T, Egashira K, Takeshita A: Vitamin C improves attenuated angiotensin II-induced endothelium-dependent vasodilation in human forearm vessels. Hypertens Res 2003; 26: 953-959.
21. Zama T, Murata M, Matsubara Y, et al: A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997; 17: 3565-3569.
22. Herrmann SM, Blanc H, Poirier O, et al: The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 1996; 126: 299-303.
23. Antikainen M, Murtomaki S, Syvanne M, et al: The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996; 98: 883-885.
24. Adams MR, Robinson J, McCredie R, et al: Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J Am Coll Cardiol 1998; 32: 123-127.
25. Mashiba J, Koike G, Kamiunten H, Ikeda M, Sunagawa K: PON1 A632G polymorphism results in amino acid substitution (Q192R) and PON1 with the 632-G allele reduces its antioxidant activity. Circ J 2005; 69: 1466-1471.
26. Mackness B, Davies GK, Turkie W, et al: Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-1457.
27. Diepgen TL, Geldmacher-von Mallinckrodt M: Interethnic differences in the detoxification of organophosphates: the human serum paraoxonase polymorphism. Arch Toxicol 1986; 9: 154-158.
28. Roy AC, Saha N, Tay JS, Ratnam SS: Serum paraoxonase polymorphism in three populations of southeast Asia. Hum Hered 1991; 41: 265-269.